Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

ContextVision – Mandatory notification of trade – primary insider

STOCKHOLM – August 11 2022 – Markus Hökerberg, CFO of ContextVision, has on August 11[th], 2022 purchased 7,000 shares in ContextVision AB at an average price of NOK 9.80 per share. After the transaction, Mr Hökerberg holds a total of 16,562 shares in ContextVision AB. With reference to Section 4-2 of the Norwegian Securities Trading Act ("STA"), kindly note the following primary insider share transaction: Name of listed entity: ContextVision ABISIN number: SE0014731154Stock ticker: CONTXName of primary insider: Markus HökerbergRelation to listed entity: CFOTrade: 7,000

Veidekke: Invitation to presentation of Q2 2022 results 18 August 2022

Veidekke ASA will report second quarter 2022 results on Thursday 18 August 2022 at 07:00 CET. The report and presentation will be made available at the same time on veidekke.com. A presentation of the quarterly results will be held at 08:00 CET at Veidekke’s head office in Skabos vei 4 at Skøyen in Oslo. All presentations will be held in Norwegian. Presentations and ensuing Q&A will be webcasted on veidekke.com. Veidekke welcomes questions to the presenters from the audience present or via web.

Immunovia, Inc. Issued Clinical and Public Health Laboratory License from California Dept of Public Health for IMMray™ PanCan-d test

LUND, SWEDEN – The California Department of Public Health has granted Immunovia, Inc., the American subsidiary of Immunovia AB (Nasdaq Stockholm: IMMNOV), a Clinical and Public Health Laboratory license, allowing physicians in California to order the IMMray PanCan-d test for their patients.   “People at risk for pancreatic cancer need better tools for early detection. We are thrilled that this approval enables us to make IMMray PanCan-d available to clinicians in California who care for those at risk.” says Jeff Borcherding, Chief Executive Officer of Immunovia, Inc.     For

Mandatory Notification of Trade - Primary Insiders

Christian Amsel, Chief Technology Officer and primary insider of Kongsberg Automotive ASA has on 10 August 2022 purchased 45,000 shares in the company at an average purchase price of EUR 0,27680. Following this transaction, Christian Amsel holds 60,000 shares in Kongsberg Automotive ASA. This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19 and section 5-12 of the Norwegian Securities Trading Act.

Invitation to telephone conference of Jetpak Top Holding AB’s second quarter report 2022

Jetpak Top Holding AB (publ) will publish its interim report for the period 1 January – 30 June 2022 on Thursday 25 August 2022 at 06:30 a.m. CET.Following this report Jetpak will organize a conference call for media and the financial community.President and CEO Kenneth Marx and CFO Håkan Mattisson will present and comment on the report.After the presentation there will be time for questions.The presentation will be held in English.Time for the publication of the year-end reportThursday 25 August 2022 at 06:30 a.m. CET.Time for conference callThursday 25 August 2022 at 10:00

Axel Johnson International strengthens offering in sensor and electric driveline solutions

Axel Johnson International’s business group Driveline Solutions expands its offering in sensor and electric driveline solutions through the acquisition of Regal Components, a Swedish provider of sensor solutions and system integrator of electric drive systems.“The acquisition of Regal Components fits well with our group strategy to expand the offering in electric drive systems, system integration and electronic components for mobile applications. With its highly skilled staff and extensive technical competence in sensors and electric drive systems, Regal Components is a great addition to

KlaraBo signs lease with Swedish Police Authority in Borlänge

KlaraBo has signed a four-year lease comprising just over 2,000 sq. m. with the Swedish Police Authority at Forskargatan 10 in Borlänge. The rental value amounts to approximately SEK 4.4 million and will increase KlaraBo’s earnings capacity by a corresponding amount as the premises have been vacant since 1 April 2022. Occupancy will begin on 1 September. In conjunction with the lease, and for the purpose of facilitating the Swedish Police Authority’s activities, KlaraBo will invest approximately SEK 2.6 million in external and perimeter protection on and in the area surrounding the

TORM plc to announce second quarter and first half 2022 results

TORM plc (“TORM”) (ticker: TRMD A on Nasdaq in Copenhagen and TRMD on Nasdaq in New York) will release its financial results for the second quarter and first half of 2022 on Thursday, 18 August 2022. TORM’s results will be presented on a live webcast via TORM’s website at 09:00 am Eastern Time / 03:00 pm Central European Time. Participants should register approximately ten minutes prior to the event. There will be a simultaneous conference call. For participation in the call, please dial +45 3271 4988 (or +1 (760) 294 1674 for US connections) at least ten minutes prior to the start to

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 149 - 11 AUGUST 2022   In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, A/S Motortramp participates by selling shares pro rata in order to maintain the current ownership of just under 32% of the shares in Dampskibsselskabet NORDEN A/S. The market will be informed accordingly – see the attached file and announcement no. 117/2022.     Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Thomas France, Investor Communications Partner, tel.: 3315 0451

Publishing of Apetit Plc’s Half-Year Report for January-June 2022 on 18 August 2022

Apetit Plc, Press release on 11 August 2022 at 10:00 a.m.Apetit Plc will publish its Half-Year Report for January-June 2022 on Thursday, 18 August 2022 at 8:30 a.m. The report can be found on the company’s website at apetit.fi after its publishing. A news conference (in Finnish) will be held as a live webcast on 18 August 2022 at 10:00. The news conference can be followed at apetit.fi/for-investors. The presentation material and a recording of the webcast will be available on the company’s website after the news conference. Apetit Plc For more information, please contact: Sanna

Axel Johnson International strengthens vehicle components offering in the Nordics

Axel Johnson International’s business group Transport Solutions strengthens its position by the acquisition of Ab Transcomponent Finland Ltd (TransComponent), a leading manufacturer of products and accessories for heavy vehicles in the Nordic market.“We are happy to welcome TransComponent to our group, this is well-aligned with our business group strategy for continued expansion. This is a well-run and profitable company that will make a good addition through its high-quality products and close customer relationships. TransComponent will complement our offering as well as enable synergies

DanCann Pharma A/S: CEO Jeppe Krog Rasmussen appointed to the board of The Danish Association of Listed Growth Companies

COPENHAGEN, Denmark, 11 August 2022 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the “Company”), a Danish company powered by cannabinoids, hereby announce that CEO Jeppe Krog Rasmussen has been appointed to the board of The Danish Association of Listed Growth Companies.The Danish Association of Listed Growth Companies has its address on the Copenhagen Stock Exchange and represents the ecosystem of companies that want to be listed on the stock exchange - or have already done so - to raise capital to finance their growth journey. DanCann Pharma A/S is represented in the association

Zalaris and CodeBot Announce Strategic Partnership to Accelerate Digital HCM Transformation through SAP SuccessFactors

Zalaris, the provider of payroll and HR solutions that simplify work life and support creating sustainable businesses, and CodeBot for SAP SuccessFactors, an SAP SuccessFactors configuration, testing, security and governance platform that accelerates cloud transformations, today announced their strategic partnership to provide solutions that can help accelerate digital HCM transformation for customers.The new partnership will allow SAP Gold Partner Zalaris to deliver SAP SuccessFactors at an accelerated timescale, achieving greater speed to value, reducing risk, and saving money. CodeBot

New case reports of ChloraSolv presented in Journal of Wound Care supplement

During the last six months, RLS Global and ConvaTec have worked in close collaboration to collect clinical experiences of ChloraSolv from three different wound centers in the UK. Six case studies have been compiled into a report and published as a supplement in Journal of Wound Care, issue no 7 2022 . The aim is to demonstrate the implementation of ChloraSolv in practice.The clinical experience shows that ChloraSolv has strong debridement efficacy, as well as good safety and ease of use. It means that the technology can be used by any

Invitation to Sensys Gatso’s presentation of the report for Q2 and the first half-year 2022

Sensys Gatso Group, a global leader in traffic safety solutions, publishes the financial report for the second quarter and first half-year 2022 at 8.30 am CET on Thursday August 18 and hereby invites to a presentation/audiocast at 10 am CET. The company’s CEO Ivo Mönnink and CFO Simon Mulder will present the financial results in English.The presentation/audiocast can be joined online or via telephone and will be available on the company’s webpage https://www.sensysgatso.com Link to the presentation/audiocast: https://tv.streamfabriken.com/sensys-gatso-group-q2-2022 Call-in details:

Cereno Scientific’s innovative Phase II study design in PAH with CS1 is accepted for presentation at the CHEST annual meeting on Oct 16-19 in Nashville, US

Cereno Scientific (XSAT: CRNO B) today announced that an abstract on clinical Phase II drug candidate CS1 has been accepted at the CHEST annual meeting 2022 hosted by the American College of Chest Physicians (CHEST) in Nashville, US, on October 16-19. The abstract has been selected for an oral presentation and is titled “An innovative Phase 2 clinical trial design for the assessment of CS1 ‒ a novel therapy in the treatment of pulmonary arterial hypertension.” It will be presented by Dr. Raymond Benza, PI of Cereno’s Phase II study in PAH with CS1 and Professor and Director of the Division of

Changes in Relais Group Management Team

Relais Group Plc, Company Release 11 August 2022 at 9.30 a.m. EEST  The following persons have been appointed to the Group Management Team of Relais Group Plc as of 11 August 2022: Johan Carlos (b. 1990), Managing Director Strands Group AB. Johan has been the Managing Director of Strands Group since 2017 and prior to that had various positions in sales and marketing at the company since 2010. Jan Popov (b. 1989), LLM, Managing Director Raskone Oy. Jan has been Managing Director of Raskone since 2018. Prior to that he worked as M&A lawyer at Eversheds Sutherland. Sebastian

Good things are worth waiting for - welcome to the second half of 2022!

We are finally entering a very exciting period for the company, as we will soon have first patient in our pivotal trial 0205, a trial that will investigate the postoperative analgesic efficacy of CT001.We obtained regulatory approval by the authorities and thereby green light at the end of June and have since then prepared the site and involved dental clinics. We are ready and hope to announce first patient within a few weeks. This will basically take the company to the next level as not that many companies are in a late-stage clinical development...Upcoming top line results of Trial 0206

Nightingale Health’s Board of Directors resolved on a change to the share-based incentive schemes

Company release, 11 August 2022 at 9:30 a.m. (EEST) Nightingale Health Plc’s (“Nightingale Health”) Board of Directors resolved to change the subscription price of shares in the company’s stock option programs. The change is applicable in all stock option programs that entitle to subscribe for Series B shares.   The new subscription price of each share in the stock option programs is EUR 2.50. Prior to the change the subscription price was EUR 6.75 per share. The subscription price is changed to maintain the purpose of the stock option programs to incentivise the option holders to

XMReality Interim report, Group overview, April – June 2022

The Annual Recurring Revenues (ARR) increased 3 percent. The Net Sales decreased by 17 percent. The Gross Margin rose from 90 percent to 95 percent.The Quarter April – June 2022, The Group · Net sales amounted to SEK 4,616 thousand (5,565) · Costs totaled SEK -18,431 thousand (-13,909) · The operating loss before appropriations and taxes was SEK -9,395 thousand (7,749) · Cash flow was SEK -12,349 thousand (-6,206) and the equity/assets ratio at the end of the period was 60.6 (80.0) percent Net sales decreased with 17 percent to SEK 4,616 thousand (5,565). The Annual

Notice to Extraordinary General Meeting in SameSystem A/S

Company Announcement No. 17-2022Copenhagen, 11 August 2022 The shareholders of SameSystem A/S are hereby convened to an extraordinary general meeting scheduled for 26 August 2022 at 14:00 am. With reference to company announcement no. 10-2022, election of new members of the board of directors is on the agenda. Please refer to the notice attached. Also, with reference to company announcement no. 10-2022, the Board of Directors has assessed the possibility of a strategic merger or sales process, including the engagement of a corporate finance advisor and discussed the options

Ruukki to invest in Nordic PIR sandwich panel production

Ruukki Construction, part of SSAB Group, is to invest EUR 15 million in sandwich panel production in Borlänge, Sweden. The new production line will be the first in Scandinavia to produce PIR sandwich panels tailored to the needs of Nordic customers. The production will come on stream in Q3 2024. Ruukki offers its customers sustainable solutions for wall and roof structures. The new production line to be built in Borlänge, Sweden will strengthen Ruukki's ability to serve customers locally in the Nordics by providing them with a dedicated product portfolio. The change will also

Aker Solutions to Provide Subsea Production System for the Trell & Trine Development

August 11, 2022 – Aker Solutions has been awarded a sizeable[1] contract from Aker BP to provide the subsea production system for the Trell & Trine field development, located in the Alvheim area of the North Sea. The development concept is a subsea tie-back to the Alvheim FPSO, using existing facilities and infrastructure.Aker Solutions will deliver a subsea production system including three horizontal subsea trees, two manifolds, control systems, close to 30 kilometers of subsea umbilicals, as well as associated equipment and installation work. The work will start immediately with final

Acquisition of TeneoTwo completed

11 August 2022 07:00 BST Acquisition of TeneoTwo for its clinical-stage T-cell engager completed AstraZeneca has completed the acquisition of TeneoTwo, Inc . (TeneoTwo)[i], including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell non-Hodgkin lymphoma.[1] AstraZeneca will develop TNB-486 as a potential new medicine for B-cell haematologic malignancies. Financial considerations

There are no items matching the current filter
There are no more items matching the current filter
Back to top